Meet Our Researchers

Sara Alcorn, MD, PhD, and Crystal Aguh, MD

Dr. Alcorn and Dr. Aguh are leading a multidisciplinary team to develop a web-based tool that will objectively assess acute skin toxicity in patients with a wide range of skin tones who are receiving radiotherapy to treat breast cancer. This unique collaboration between the Department of Radiation Oncology and the Department of Dermatology aims to improve quality of life for patients across the range of skin tones and is being supported by an ROI Improving Diversity and Inclusion in Radiation Oncology grant. 

Carmen Bergom, MD, PhD, and El-Sayed Ibrahim, PhD

Dr. Bergom, Dr. Ibrahim and their team are conducting a pilot study to determine whether advanced cardiac MRI can be used to detect early, non-symptomatic damage to the heart in lung cancer patients treated with radiation therapy. They are working to better understand how radiation therapy affects the heart so that treatment plans can be personalized to reduce damage to the heart and improve long-term outcomes among patients with lung cancer.

David Byun, MD

Dr. Byun and his team are exploring whether the application of virtual and augmented reality platforms during consultation visits could better increase patient knowledge about radiation therapy, reduce anxiety, and improve the quality of their overall treatment experience.Their CurieUx mixed reality patient education software is designed to include a novel virtual reality 360° tour of simulation and treatment rooms for patients to explore, as well as interactive virtual disease-specific anatomy models to help physicians personalize their verbal explanation of each patient's diagnosis and treatment.

Fumiko Chino, MD, and Yvonne Mowery, MD, PhD

Dr. Chino, Dr. Mowery and their team are prospectively quantifying and investigating the effects of financial toxicity—a term for the hardship that patients face from their medical expenses—for head and neck cancer patients. The ROI is supporting the team's work as part of the 2018 Innovative Projects in Radiation Oncology awards, which focused on funding research to address some of the field’s most pressing challenges.

Peter Greer, PhD

Dr. Greer and his team are developing the WatchDog system that determines treatment delivery accuracy for radiation therapy patients in real-time and can prevent mistreatment. Dr. Greer received ROI’s inaugural research award to conduct the team’s first clinical demonstration of the WatchDog system as part of the ROI’s safety and quality initiative.

Daniel Golden, MD, MHPE

Dr. Golden and his team are improving communication between patients with cancer and their physicians by developing a personalized discussion guide that explains external beam radiotherapy in an easy-to-digest format. With the grant from the ROI, the team is creating three new guides in the “Communicating the External Beam Radiotherapy Experience” (CEBRE) series that are tailored for patients with breast, lung and prostate cancer. The guides will provide understandable information unique to the patient’s disease site and treatment process in a graphic narrative format.

Karen Hoffman, MD, MHSc, MPH

Dr. Hoffman and her team are prospectively surveying prostate cancer patients to study how receiving counseling from a radiation oncologist in a multidisciplinary clinic increases their awareness of radiation therapy as a treatment option with a favorable side effect profile and whether it changes their treatment choice. The ROI selected Dr. Hoffman’s research for a 2018 Innovative Projects in Radiation Oncology award because of its emphasis on raising the profile of radiation therapy among patients.

Amar Kishan, MD

Dr. Kishan received the 2018 Publication Award in recognition of the outstanding research published in the manuscript, “Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.” As first author of the article, Dr. Kishan received a grant to build upon the research in the manuscript, which he is using to expand the multi-institutional consortium that he established and extend the investigation to the general category of high-risk prostate cancer.

Geoffrey Martin, MD

Dr. Martin and his team conducted a clinical trial using smartphone-connected technology to monitor lung cancer patients undergoing radiation therapy. ROI awarded Dr. Martin an Innovative Projects in Radiation Oncology grant to investigate the correlation between patient reported outcomes, the continuous biometric monitoring via smartphones and the side effects of radiation therapy.

Malcolm Mattes, MD

Dr. Mattes and his team are launching a program to develop a more diverse radiation oncology workforce by introducing African American and Latinx students to the specialty earlier in medical school. They will take a multifaceted approach and will study the perceived value of each of the initiatives as well as the impact of the program on radiation oncology residency applications and matches. The ROI selected Dr. Mattes' work for funding through the Improving Diversity and Inclusion in Radiation Oncology request for proposals. 

Todd McNutt, PhD

Dr. McNutt and his team are using big data and machine learning approaches to develop better predictive models for toxicities associated with head and neck cancer and to create a clinical decision support tool to help provide patients with more personalized care. The ROI is supporting Dr. McNutt’s groundbreaking work to stimulate this emerging field of research using big data to improve the safety and quality of radiation therapy.

Nima Nabavizadeh, MD

Dr. Nabavizadeh and his team are prospectively studying whether stereotactic body radiation therapy (SBRT) can be safely used to help patients with hepatocellular carcinoma (HCC) and advanced cirrhosis as they await a liver transplant. The ROI is supporting Dr. Nabavizadeh’s work as part of the 2018 Innovative Projects in Radiation Oncology awards, which sought to address some of radiation oncology’s highest priority topics, including SBRT.

Nitin Ohri, MD

Dr. Ohri and his team are conducting a randomized clinical trial to determine if giving patients daily customized step count goals as measured and guided through fitness trackers could improve patients’ ability to tolerate concurrent chemoradiotherapy. With an Innovative Projects in Radiation Oncology grant from ROI, Dr. Ohri is exploring whether this relatively simple intervention can reduce the number of missed treatments, decrease treatment-related toxicities and improve quality of life for cancer patients.

Oluwadamilola T. Oladeru, MD, MA

Dr. Oladeru and her team are studying cancer care in the federal prison system by measuring the cancer incidence and mortality, characterizing the utilization of radiation treatment, describing patterns of disease presentation and disparities in access to care, and developing an integrated value-based model for cancer care delivery. Dr. Oladeru is the first ever James D. Cox Resident's Research Award Winner and her project was selected for funding through the ROI's Improving Diversity and Inclusion in Radiation Oncology request for proposals. 

G. Nic Rider, PhD, and Stephanie Terezakis, MD

G. Nic Rider, PhD, and Stephanie Terezakis, MD, of the University of Minnesota – Twin Cities are evaluating disparities in cancer care for patients who identify as lesbian, gay, bisexual, transgender, queer, and/or questioning (LGBTQ+). Their qualitative study will provide rich information about the training needs of various health care providers to deliver more competent, quality care to LGBTQ+ patients with cancer.

Malolan S. Rajagopalan, MD, MBA

Dr. Rajagopalan developed the RadOnc Toolbox app that features evidence-based interventions for managing and preventing eight of the most common radiation-related toxicities and a number of other clinical tools. The ROI supported the development of the RadOnc Toolbox to provide practitioners with an evidence-based resource for toxicity management in order to improve outcomes for cancer patients and survivors.

Anand Shah, MD, MPH

Dr. Shah and his team developed novel episode-based Medicare payment definitions for stereotactic body radiation therapy (SBRT) to treat patients with early stage non-small cell lung cancer (NSCLC). As part of ROI’s value of radiation therapy initiative, Dr. Shah’s study included an exploration of whether an academic versus nonacademic setting has an impact on the relative value of SBRT compared with surgery.

David Sher, MD, MPH

Dr. Sher and his team conducted parallel comparative effectiveness and cost comparison studies for early-stage and locally advanced oropharyngeal cancer using two large databases, SEER-Medicare and the HealthCore Integrated Research Database (HIRD). The results from Dr. Sher’s ROI-funded study are providing important evidence about the value of radiation therapy in the treatment of oropharyngeal cancer.

Christopher Slatore, MD, MS

Dr. Slatore and his team conducted a comparative, mixed-method study to better understand the patient-centered outcomes associated with radiation therapy versus surgery for early stage non-small cell lung cancer (NSCLC.) Dr. Slatore's ROI-funded work on the value of radiation therapy for the treatment of lung cancer laid the groundwork for additional research now being supported by the National Cancer Institute.

Chad Tang, MD

Dr. Tang and his team are conducting an analysis to understand the barriers to access and costs associated with four treatment options for patients with prostate cancer—surgery, external beam radiation therapy, brachytherapy and active surveillance. The ROI is supporting Dr. Tang’s work as part of the 2018 Innovative Projects in Radiation Oncology awards, which focused on funding research to address some of the field’s most pressing challenges.

K. Ranh Voong, MD, MPH

Dr. Voong received the Outstanding Article Award in the 2017 ROI Value of RT Publication Awards in partnership with Advances in Radiation Oncology. She was honored for her work as the lead author on the manuscript titled, “Long-term Economic Value of Hypofractionated Prostate Radiation: Secondary Analysis of a Randomized Trial,” and received a grant to continue her research on the value of radiation therapy.

Adam Wolfe, MD, PhD

Adam Wolfe, MD, PhD, and his team are conducting research that will help personalize treatments for patients with pancreatic cancer. Their work aims to identify which pancreatic cancer patients could benefit the most from radiation therapy following surgery using a new molecular signature that they discovered and is made up of microRNAs found in blood and tumor tissue samples. Dr. Wolfe's research is supported by a 2019 ROI Personalized Radiation Therapy award.